PBF (1760) reported revenue of NT$156.2 million for Oct 2026, +16.7% year on year and +13.9% from the previous month. Revenue for Jan–Oct 2026 was NT$1.68 billion (+1.7% year on year).
In Oct 2026, it ranked No. 52 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$156.2 million | +16.7% | +13.9% |
| Sep 2026 | NT$137.2 million | +1.1% | -24.3% |
| Aug 2026 | NT$181.2 million | -27.9% | +4.6% |
| Jul 2026 | NT$173.2 million | +19.6% | +30.5% |
| Jun 2026 | NT$132.7 million | -4.0% | -43.4% |
| May 2026 | NT$234.5 million | +1.8% | +62.1% |
| Apr 2026 | NT$144.6 million | +7.0% | -3.5% |
| Mar 2026 | NT$149.8 million | +17.1% | -35.6% |
| Feb 2026 | NT$232.7 million | -4.5% | +70.1% |
| Jan 2026 | NT$136.8 million | +24.3% | -24.0% |
| Dec 2025 | NT$180 million | +14.9% | -22.6% |
| Nov 2025 | NT$232.4 million | -1.3% | +73.7% |
| Oct 2025 | NT$133.8 million | +2.6% | -1.4% |
| Sep 2025 | NT$135.8 million | +3.7% | -46.0% |
| Aug 2025 | NT$251.3 million | +4.6% | +73.5% |
| Jul 2025 | NT$144.9 million | -4.8% | +4.8% |
| Jun 2025 | NT$138.2 million | +10.0% | -40.0% |
| May 2025 | NT$230.4 million | -1.6% | +70.4% |
| Apr 2025 | NT$135.2 million | +8.8% | +5.7% |
| Mar 2025 | NT$127.9 million | +4.7% | -47.5% |
| Feb 2025 | NT$243.5 million | +6.8% | +121.2% |
| Jan 2025 | NT$110.1 million | -26.2% | -29.7% |
| Dec 2024 | NT$156.6 million | +13.9% | -33.5% |
| Nov 2024 | NT$235.5 million | -5.8% | +80.6% |
| Oct 2024 | NT$130.4 million | -7.6% | -0.4% |
Jan–Oct 2026 cumulative: NT$1.68 billion (+1.7% YoY)
Other Biotech & Medical companies
Compare with peers: PBF vs PEC / PBF vs Lotus Pharm / PBF vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16